Memantine Merz

Memantine, the active ingredient in Memantine Merz, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, helping to reduce excitotoxic neuronal damage associated with disease progression. It may be used as part of a comprehensive care plan.

GNH USA supplies Memantine Merz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality, regulatory compliance and timely delivery across multiple regions.

Memantine is used in the management of Alzheimer’s disease, targeting glutamatergic neurotransmission to improve cognitive function.

- Moderate to severe Alzheimer’s disease: helps slow cognitive decline and functional deterioration. - Combination therapy with cholinesterase inhibitors: provides additional cognitive benefit when used together. - Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression associated with disease progression.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate cranial pain. - Constipation: reduced bowel movements. - Confusion: transient disorientation or difficulty concentrating. - Somnolence: increased sleepiness or fatigue.

Serious or Rare Side Effects: - Seizures: occurrence of convulsive episodes. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: serious skin and mucous membrane disorder. - Hepatic dysfunction: abnormal liver enzyme elevations. - Cardiac arrhythmias: irregular heart rhythm potentially requiring medical attention.

Memantine should be used with caution in specific clinical situations.

- Renal impairment: assess kidney function and consider dose adjustment. - History of seizures: monitor for increased seizure activity. - Concurrent NMDA antagonists: avoid additive neuro‑psychiatric effects. - Pregnancy: prescribe only if the potential benefit justifies the potential risk to the fetus. - Elderly patients: initiate therapy at the lowest effective dose and titrate slowly. - Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Memantine may interact with other medications that affect the central nervous system or NMDA pathways.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism can increase neuro‑psychiatric adverse effects. - Ketamine: additive CNS depression and dissociative symptoms. - Other NMDA receptor antagonists: heightened risk of severe side effects.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible enhancement of hypotensive effect. - CNS depressants (e.g., benzodiazepines): increased sedation or drowsiness. - Acetylcholinesterase inhibitors: may reduce therapeutic efficacy of memantine.